Danaher (NYSE:DHR) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

by · The Markets Daily

Danaher (NYSE:DHR – Get Free Report) announced its quarterly earnings results on Tuesday. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19, FiscalAI reports. The company had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%.

Danaher Stock Up 0.2%

Shares of Danaher stock opened at $224.78 on Wednesday. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The stock has a market cap of $158.02 billion, a price-to-earnings ratio of 39.93, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a fifty day moving average price of $214.70 and a 200 day moving average price of $196.54.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

Analyst Ratings Changes

Several brokerages have weighed in on DHR. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. TD Cowen boosted their price target on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Barclays raised their price objective on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Check Out Our Latest Research Report on DHR

Danaher Company Profile

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Read More